These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9619822)

  • 21. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2.
    Rodés B; Toro C; Jiménez V; Soriano V
    Clin Infect Dis; 2005 Jul; 41(2):e19-21. PubMed ID: 15983906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
    Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
    AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
    [No Abstract]   [Full Text] [Related]  

  • 24. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.
    Masquelier B; Pereira E; Peytavin G; Descamps D; Reynes J; Verdon R; Fleury H; Garraffo R; Chêne G; Raffi F; Brun-Vézinet F;
    J Clin Virol; 2005 May; 33(1):75-8. PubMed ID: 15797369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 26. [Antiretroviral therapy of HIV-infections].
    Rockstroh JK
    Pharm Unserer Zeit; 2000 Sep; 29(5):284-96. PubMed ID: 11077473
    [No Abstract]   [Full Text] [Related]  

  • 27. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
    Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shedding of HIV-1 in semen during primary infection.
    Dyer JR; Gilliam BL; Eron JJ; Cohen MS; Fiscus SA; Vernazza PL
    AIDS; 1997 Mar; 11(4):543-5. PubMed ID: 9084808
    [No Abstract]   [Full Text] [Related]  

  • 29. Vaginal HIV-1 shedding among HIV-1 infected women in the current era of combined antiretroviral therapy: A cross sectional study.
    Grignolo S; Bruzzone B; Gabbi L; Gerbaldo D; Gallo F; Nigro N; Icardi G; Viscoli C; Di Biagio A
    Virulence; 2017 Jan; 8(1):101-108. PubMed ID: 27459346
    [No Abstract]   [Full Text] [Related]  

  • 30. Surrogacy in HIV-1 clinical trials.
    Pozniak A
    Lancet; 1998 Feb; 351(9102):536-7. PubMed ID: 9492766
    [No Abstract]   [Full Text] [Related]  

  • 31. Quantification of HIV-1 RNA in cervicovaginal secretions: an improved method of sample collection.
    O'Shea S; de Ruiter A; Mullen J; Corbett K; Chrystie I; Newell ML; Banatvala JE
    AIDS; 1997 Jul; 11(8):1056-8. PubMed ID: 9223743
    [No Abstract]   [Full Text] [Related]  

  • 32. The time has come. One world, one hope.
    Elliott EB
    Can Fam Physician; 1996 Nov; 42():2302-3. PubMed ID: 8939327
    [No Abstract]   [Full Text] [Related]  

  • 33. Viral escape in cerebrospinal fluid--an achilles heel of HIV therapy?
    Clifford DB
    J Infect Dis; 2010 Dec; 202(12):1768-9. PubMed ID: 21050117
    [No Abstract]   [Full Text] [Related]  

  • 34. Directly observed antiretroviral therapy to reduce genital tract and plasma HIV-1 RNA in women with poor adherence.
    Harwell JI; Flanigan TP; Mitty JA; Macalino GE; Caliendo AM; Ingersoll J; Stenzel MS; Carpenter CC; Cu-Uvin S
    AIDS; 2003 Sep; 17(13):1990-3. PubMed ID: 12960835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women.
    Min SS; Corbett AH; Rezk N; Cu-Uvin S; Fiscus SA; Petch L; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2004 Dec; 37(5):1577-80. PubMed ID: 15577412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 viral load and clinical outcome: review of recent studies.
    Riddler SA; Mellors JW
    AIDS; 1997; 11 Suppl A():S141-8. PubMed ID: 9451978
    [No Abstract]   [Full Text] [Related]  

  • 37. In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor-based versus non-protease inhibitor-based highly active antiretroviral therapy.
    Ananworanich J; Nuesch R; Teeratakulpisarn S; Srasuebkul P; Chuenyam T; Siangphoe U; Ungsedhaphand C; Phanuphak P; Ruxrungtham K
    J Acquir Immune Defic Syndr; 2003 Apr; 32(5):570-2. PubMed ID: 12679711
    [No Abstract]   [Full Text] [Related]  

  • 38. Definition of virologic response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy. APROCO Study Group.
    Le Moing V; Chêne G; Masquelier B; Sicard D; Brun-Vézinet F; Reynes J; Raffi F
    J Acquir Immune Defic Syndr; 2000 May; 24(1):82-3. PubMed ID: 10877502
    [No Abstract]   [Full Text] [Related]  

  • 39. Viral load and response to treatment of HIV.
    Ioannidis JP; Cappelleri JC; Lau J
    N Engl J Med; 1996 Jun; 334(25):1671; author reply 1672-3. PubMed ID: 8628372
    [No Abstract]   [Full Text] [Related]  

  • 40. Instantaneous inhibitory potential and inhibitory quotient show a modest association with virologic outcome: is either a useful surrogate for clinical drug efficacy?
    MacArthur RD
    Clin Infect Dis; 2010 Jul; 51(1):99-100. PubMed ID: 20504164
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.